Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.61 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | PDE1A | P54750 | 1/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18210780 | 1.00 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3ACHEMEN1 | |
| SCHEMBL12127337 | 0.98 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3ACHEMEN1 | |
| SCHEMBL8352183 | 0.94 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3ACHEALDH1A1 | |
| SCHEMBL12127336 | 0.90 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3ACHEALDH1A1 | |
| SCHEMBL11663045 | 0.86 | SLC6A4 (0.47) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL13450921 | 0.84 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3ACHEALDH1A1 | |
| SCHEMBL22859969 | 0.82 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3ACHEMEN1 | |
| SCHEMBL8264651 | 0.82 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3ACHEKMT2A | |
| SCHEMBL8358502 | 0.82 | HRH1 (0.62) | SLC6A2SLC6A4SLC6A3ACHENAAA | |
| SCHEMBL3121897 | 0.82 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3ACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| EP-2970114-B1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-15 | — | — | EP | disclosed |
| US-9802952-B2 | Method and apparatus for the synthesis of dihydroartemisinin and artemisinin derivatives | Max-Plank-Gesellschaft zur Förderung der Wissenschaften e.v. (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9802952-B2 | Method and apparatus for the synthesis of dihydroartemisinin and artemisinin derivatives | Max-Plank-Gesellschaft zur Förderung der Wissenschaften e.v. (DE) | 2017-10-31 | — | — | US | disclosed |
| EP-3022208-B1 | METHOD AND APPARATUS FOR THE SYNTHESIS OF DIHYDROARTEMISININ AND ARTEMISININ DERIVATIVES | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS (DE) | 2017-06-14 | — | — | EP | disclosed |
| US-9624188-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160145265-A1 | METHOD AND APPARATUS FOR THE SYNTHESIS OF DIHYDROARTEMISININ AND ARTEMISININ DERIVATIVES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-05-26 | — | — | US | disclosed |
| US-20160145265-A1 | METHOD AND APPARATUS FOR THE SYNTHESIS OF DIHYDROARTEMISININ AND ARTEMISININ DERIVATIVES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-05-26 | — | — | US | disclosed |
| WO-2015007693-A1 | METHOD AND APPARATUS FOR THE SYNTHESIS OF DIHYDROARTEMISININ AND ARTEMISININ DERIVATIVES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-01-22 | — | — | WO | disclosed |
| US-7459580-B2 | Process for trans-4-amino-1-cyclohexanecarboxilic acid derivatives | SHIONOGI & CO., LTD. (JP) | 2008-12-02 | — | — | US | disclosed |
| US-7459580-B2 | Process for trans-4-amino-1-cyclohexanecarboxilic acid derivatives | SHIONOGI & CO., LTD. (JP) | 2008-12-02 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080262264-A1 | Process For the Preparation of Sulfomate-Carboxylate Derivatives | SHIONOGI & CO., LTD. (JP) | 2008-10-23 | — | — | US | disclosed |
| US-20080262264-A1 | Process For the Preparation of Sulfomate-Carboxylate Derivatives | SHIONOGI & CO., LTD. (JP) | 2008-10-23 | — | — | US | disclosed |
| US-20080039662-A1 | PROCESS FOR TRANS-4-AMINO-1-CYCLOHEXANECARBOXILIC ACID DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2008-02-14 | — | — | US | disclosed |
| US-20080039662-A1 | PROCESS FOR TRANS-4-AMINO-1-CYCLOHEXANECARBOXILIC ACID DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2008-02-14 | — | — | US | disclosed |
| US-7314950-B2 | Process for producing trans-4-amino-1-cyclohexanecarboxilic acid derivative | SHIONOGI & CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| US-7314950-B2 | Process for producing trans-4-amino-1-cyclohexanecarboxilic acid derivative | SHIONOGI & CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| US-4111966-A | DYES FOR POLYESTERS | CIBA-GEIGY CORPORATION (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY2 | SLC6A2 2695/4885SLC6A4 2416/4885SLC6A3 3160/4885 |
| US-20080039662-A1 | PROCESS FOR TRANS-4-AMINO-1-CYCLOHEXANECARBOXILIC ACID DERIVATIVES | AADAT, ACMSD, AAAS | SLC6A2 2018/4885SLC6A4 1119/4885SLC6A3 3153/4885 |
| US-20080262264-A1 | Process For the Preparation of Sulfomate-Carboxylate Derivatives | STS, ADH1C, ADH1A | SLC6A2 3555/4885SLC6A4 2081/4885SLC6A3 1837/4885 |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | SLC6A2 415/4885SLC6A4 642/4885SLC6A3 911/4885 |
| US-20160145265-A1 | METHOD AND APPARATUS FOR THE SYNTHESIS OF DIHYDROARTEMISININ AND ARTEMISININ DERIVATIVES | ADH1A, DHODH, DHPS | SLC6A2 4084/4885SLC6A4 4252/4885SLC6A3 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.